Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplastic sensory neuropathy (NESPA). - APHP230701

Assistance Publique Hopitaux De Paris0 个研究点目标入组 21 人开始时间: 2023年11月10日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Adult patients with anti-Hu antibody paraneoplastic sensory neuropathy, Age = 18 years old, Possible sensory neuropathy according to the criteria of Camdessanché et al., dominant picture of sensitive ataxia (damage to the central nervous system and/or neuromuscular junction is accepted, provided that it has a minor impact on the patient's disability), Positive anti-Hu antibodies in blood and/or cerebrospinal fluid, Outpatient (Modified Rankin Score (mRS) 2 or 3), Start of neurological symptoms less than 3 months ago, Inform consent Free, written and signed, Registered with a social security scheme or beneficiary (except AME)

•Known hypersensitivity to one of the treatments under study, to their metabolites, or to one of the excipients, Patients unable to complete the follow-up required by the study, Patients under tutorship or curatorship, Patient deprived of liberty by a judicial or administrative decision, Absolute contraindications to IVIg: selective IgA deficiency, known thrombophilia, patients suffering from type I or II hyperprolinaemia, hypersensitivity to human immunoglobulins, Absolute contraindications to cyclophosphamide: yellow fever vaccination within three months of inclusion, acute urinary tract infection, acute bone marrow failure, More than two courses of intravenous Immunoglobulins administered in the 3 months prior to recruitment, Other concomitant immunotherapy, Other causes of immunodepression (acquired or congenital), Treatment with checkpoint inhibitors in progress or completed less than 3 months previously, Women of childbearing age without effective contraception, pregnant or breastfeeding, History of psychiatric or general illness that may contraindicate treatment

发起方